Package Leaflet: Information for the User
Pentasa 1g prolonged-release granules
Mesalazine
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack
Pentasa sachets are indicated for the treatment of mild to moderate ulcerative colitis flare-ups and to help maintain you free of new flare-ups.
Ulcerative colitis is an inflammatory bowel disease in which the lining of the intestine is inflamed and develops many small breaks in its surface (ulcers) that can bleed.
Pentasa sachets contain granules that release the active ingredient (mesalazine) slowly. This helps to reduce inflammation and painful symptoms.
Do not take Pentasa
Warnings and precautions
Consult your doctor or pharmacist before taking Pentasa:
Mesalazine may cause a discoloration of the urine to a reddish-brown color after contact with sodium hypochlorite bleach in the toilet water. This is a chemical reaction between mesalazine and bleach and is harmless.
Be careful with mesalazine:
Severe skin reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SSJ), and toxic epidermal necrolysis (TEN), have been observed with mesalazine treatment. Stop taking mesalazine and seek medical attention immediately if you notice any of the symptoms related to these severe skin reactions described in section 4.
While you are on treatment with this medicine, your doctor will normally perform blood and urine tests to monitor your kidney function, especially at the start of treatment.
Interaction of Pentasa with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. This is especially important if you are taking any of the following medicines:
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
There is limited experience with the use of mesalazine during pregnancy and breastfeeding.
Blood disorders have been observed in newborns of mothers treated with this medicine. Newborns may develop allergic reactions after breastfeeding, e.g. diarrhea. If the newborn has diarrhea, breastfeeding should be discontinued.
Driving and using machines:
This medicine is not known to affect the ability to drive or use machines.
Follow the instructions for administration of this medicine exactly as prescribed by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
Adults:
To treat a flare-up of colitis,your doctor will normally prescribe a dose of up to 4g of mesalazine per day, which can be taken either once daily or divided into two doses. It can be taken as two Pentasa 2g sachets once daily.
Pentasa 1g prolonged-release granules can also be used to provide the dose that best suits you.
To help you stay free of further flare-ups, your doctor may prescribe 2g of mesalazine per day, administered as one Pentasa 2g sachet or two Pentasa 1g sachets once daily.
Children and adolescents (aged 6 years and above):
For children and adolescents, the dose will be calculated by your doctor based on body weight. The recommended dose in children and adolescents with a body weight of up to 40kg will be half the usual recommended dose in adults, and for those with a body weight above 40kg, the dose will be the same as the usual recommended dose in adults.
You should take the granules orally (by mouth),immediately after opening the sachet, as described below. Do not chew the granules.
Or
If you take more Pentasa sachets than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, stating the medicine and the amount taken.
If you forget to take Pentasa sachets
If you have forgotten to take a dose, take it as soon as you remember, and then take the next dose at the usual time. Do not take a double dose to make up for the forgotten dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Pentasa sachets can cause side effects, although not everybody gets them.
Very rare cases of severe allergic reactions (including severe skin reactions that can affect the skin as a protective barrier of the body) have been reported. The allergic reaction could lead to swelling of the face and neck and/or difficulty breathing or swallowing (angioedema). If this happens, contact your doctor or emergency services immediately.
Stop taking mesalazine and seek medical attention immediately if you experience any of the following symptoms: reddish patches, or circular or coin-shaped patches on the chest, often with central blisters, skin peeling, ulcers in the mouth, throat, nose, genitals, and eyes, generalized rash, fever, and swollen lymph nodes. These severe skin reactions are often preceded by fever or flu-like symptoms.
The following side effects are common(affect 1 to 10 users in 100):
The following side effects are rare(affect 1 to 10 users in 1,000):
The following side effects are very rare(affect less than 1 user in 1,000):
Frequency not known (cannot be estimated from the available data)
Isolated cases of benign intracranial hypertension (increase in fluid around the brain) have been reported in adolescents. Symptoms include headache, nausea, vomiting, and/or visual or auditory disturbances.
Reporting of side effects:
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines and Healthcare Products Agency (AEMPS) website: http://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the packaging and on the aluminum sachet. The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to your pharmacist. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Pentasa sachets
The active substance is mesalazine.
Each sachet contains 1g of mesalazine.
The other ingredients are ethylcellulose and povidone
Appearance of the product and pack contents
This medicine contains prolonged-release granules. The granules are white or pale brown and cylindrical in shape.
This medicine is available in aluminum sachets in packs of:
1g sachets: 50 or 100
FERRING S.A.U
C/ del Arquitecto Sánchez Arcas 3, 1º
Madrid 28040
Ferring GmbH
Wittland 11
D-24109 Kiel
Germany
This medicine is authorized in the Member States of the European Economic Area under the following names:
Quintasa Sachets: Denmark
Pentasa Sachets: Cyprus, Germany, Greece, Ireland, Spain, Sweden, United Kingdom (Northern Ireland)
Pentasa: Slovenia
The last revision of this leaflet was in January 2023.
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/
The average price of PENTASA 1g PROLONGED-RELEASE GRANULES in October, 2025 is around 79.85 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.